Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

The Dow, S&P 500, and Nasdaq rose Thursday as the stock market digested data on retail sales and jobless claims.

Sarepta's stock is jumping Thursday morning after the company announced a restructuring plan. Thomas Fuller / SOPA Images / LightRocket via Getty Images ...

Sarepta Therapeutics SRPT -2.17% is restructuring, laying off 36% of its workforce and making changes to its executive team. The restructuring is expected to save $400 million a year, the gene ...

Nevertheless, this heightened reliance on Elevidys, which accounted for 43% of Sarepta's total revenues, increases risks should any additional safety issues arise.

In the latest quarter, 35 analysts provided ratings for Sarepta Therapeutics SRPT, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

Some Connecticut lawmakers are now balking at immigration enforcement they see as heavy-handed and in conflict with people's legal rights.

TSMC shares rose 4% in premarket trade as the contract chip manufacturer lifted its 2025 sales guidance. Sarepta Therapeutics stock jumped 34% as the company set plans to lay off more than a third ...

↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an investment analysis.